Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec